A novel double-target CAR-T cell therapy has been developed, recognizing GPC3 (a protein upregulated in HCC) and inhibiting PD-1, demonstrating superior therapeutic effects on HCC compared to single-target CAR-T cells. This evidence concerns the gene GPC3 and hepatocellular carcinoma.